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Abstract: Despite efforts to improve hygenic conditions and regulate food and drinking 
water safety, the enteric pathogens, Shiga toxin-producing Escherichia coli (STEC) and 
Shigella dysenteriae serotype 1 remain major public health concerns due to widespread 
outbreaks and the severity of extra-intestinal diseases they cause, including acute renal 
failure and central nervous system complications. Shiga toxins are the key virulence factors 
expressed by these pathogens mediating extra-intestinal disease. Delivery of the toxins to 
the endoplasmic reticulum (ER) results in host cell protein synthesis inhibition, activation 
of the ribotoxic stress response, the ER stress response, and in some cases, the induction of 
apoptosis. Intrinsic and/or extrinsic apoptosis inducing pathways are involved in executing 
cell death following intoxication. In this review we provide an overview of the current 
understanding Shiga toxin intracellular trafficking, host cellular responses to the toxin and 
ER stress-induced apoptosis with an emphasis on recent findings. 
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1. Introduction 
Shiga  toxins  (alternatively  called  verotoxins  or  Shiga-like  toxins)  are  major  virulence  factors 
expressed  by  the  enteric  pathogens  Shigella  dysenteriae  serotype  1  and  certain  serotypes  of 
Escherichia  coli.  Shiga  toxin-producing  bacteria  constitute  a  significant  public  health  concern  in 
developing and developed countries. In particular, the presence of Shiga toxin-producing Escherichia 
coli (STEC) in the food supply may cause widespread outbreaks of disease. Infection of humans with 
as few as 10–100 organisms of Shigella dysenteriae serotype 1 or STEC may initially cause bloody 
diarrhea which may progress, particularly in children and the elderly, to a form of acute renal failure 
which  is  called  the  hemolytic  uremic  syndrome  (HUS),  and  may  be  followed  by  neurological 
complications  in  severe  cases.  HUS  is  characterized  by  the  clinical  triad  of  thrombotic 
microangiopathy, hemolytic anemia and thrombocytopenia [1–3]. Nervous system complications may 
include lethargy, disorientation, seizures, and paralysis [4]. The toxins appear capable of crossing the 
intact intestinal epithelial barrier via transcytotic or paracellular mechanisms [5,6], damage the colonic 
microvasculature [7,8], may then associate with blood monocytes and neutrophils to circulate in the 
bloodstream [9,10], and bind to susceptible cells via a unique toxin-binding glycosphingolipid receptor 
[11].  Microvascular  endothelial  cells  within  the  kidneys  and  central  nervous  system  appear  to  be 
preferentially sensitive to the cytotoxic action of Shiga toxins. Once internalized, the toxins undergo 
retrograde intracellular trafficking to reach the lumen of the endoplasmic reticulum (ER) [12].  
There are no vaccines to prevent disease caused by Stx-producing bacteria. Furthermore, treatment 
of the disease is primarily supportive, e.g., hemodialysis or peritoneal dialysis for HUS. Treatment 
with anti-motility agents and antibiotics are contraindicated in disease caused by Shiga toxins [1–3]. In 
order  to  define  new  targets  for  intervention  in  disease  progression,  extensive  efforts  have  been 
undertaken  by  researchers  to  better  understand  the  mechanism  of  action,  intracellular  trafficking, 
activation of host intracellular signaling pathways, and the elicitation of the innate immune response 
by Shiga toxins (reviewed in [13]). Interventional strategies currently under development to block 
disease  caused  by  Shiga  toxins  may  be  categorized  as:  (i)  toxin  receptor  analogues;  (ii)  toxin 
intracellular transport inhibitors; (iii) anti-toxin antibodies; and (iv) probiotic bacteria. Initial attempts 
to  create  a  toxin  receptor  analogue  involved  the  coupling  of  the  Galα(1→4)Galβ(1→4)Glu 
trisaccharide  of  Gb3  to  inert  diatomaceous  earth  for  oral  administration  to  patients  with  bloody 
diarrhea[14]. This product is called Synsorb-Pk. The hypothesis was that Synsorb-Pk would bind free 
Shiga toxins in the intestinal tract and facilitate toxin removal. Unfortunately, Synsorb-Pk was not 
proven effective in clinical trials [15,16]. It was subsequently shown that Shiga toxins are capable of 
translocation  across  polarized  intestinal  epithelial  monolayers  [5,6]  suggesting  that  toxin  receptor 
analogues  may  be  more  efficacious  if  delivered  intravenously.  In  this  regard,  Nishikawa  and 
colleagues used carbosilane dendrimers to create highly branched compounds containing multiple Gb3 
trisaccharides [17]. These compounds protected mice from a lethal dose of purified Stx2. Saenz et al. 
[18] screened over 14,000 low molecular compounds to identify two compounds that blocked Shiga 
toxin  intracellular  transport  at  different  steps.  One  compound  blocked  toxin  transport  at  the  early 
endosome step, while the second compound blocked translocation through the Golgi apparatus. Several 
investigators have developed anti-Shiga toxin humanized monoclonal antibodies. Mukherjee et al. [19] 
screened a panel of ten anti-Stx1 humanized monoclonals and showed them all to be effective in Toxins 2010, 2                         
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neutralization of Stx1 in vitro and in protection of toxin challenged mice. A recombinant E. coli K-12 
strain was engineered to express a modified LPS structure which binds Shiga toxins with high affinity 
[20].  When  fed  to  mice,  this  recombinant  strain  protected  the  animals  from  oral  challenge  with  
Stx2-producing E. coli. Readers are referred to a recent review for more information on interventional 
strategies [13]. Despite these advancements, however, infections with Shiga toxin-producing bacteria 
are still a significant cause of morbidity and mortality. The development of effective drugs or vaccines 
to prevent or treat diseases caused by Shiga toxins will require an increased understanding of the 
interaction of the toxins with multiple cell types. 
2. Characterization of Shiga Toxin Intracellular Transport 
2.1. Toxin Structure and Function 
The Shiga toxins constitute a family of genetically and functionally related cytotoxins. Shigella 
dysenteriae  serotype  1  expresses  the  prototypical  member  of  the  family,  Shiga  toxin,  and  is  the 
causative agent of bacillary dysentery. STEC, of which Escherichia coli O157:H7 strains are most 
common in many countries, express one or more toxins that are closely related to Shiga toxin [21]. 
However, non-O157 serotype enterohemorrhagic Escherichia coli (EHEC) have been associated with 
HUS  and  recently,  a  reference  collection  of  HUS-associated  EHEC  (HUSEC)  strains  has  been 
established by performing multilocus sequencing typing (MLST) [22]. Toxins expressed by STEC are 
antigenically categorized as Shiga toxin type 1 (Stx1), which is essentially identical to Shiga toxin, and 
Shiga toxin type 2 (Stx2), which possesses approximately 56% identity to Shiga toxin/Stx1 at the 
deduced amino acid sequence level [23]. A number of genetic variants of Stx1 and Stx2 have been 
characterized.  X-ray  crystallographic  analyses  revealed  that  all  Shiga  toxins  contain  six  protein 
subunits  in  an  AB5  molecular  configuration.  Thus,  all  Shiga  toxins  contain  a  single,  enzymatic  
A-subunit in non-covalent association with a homopentamer of B-subunit proteins [24–26]. Toxin  
A-subunits are potent protein synthesis inhibitors which act by cleaving a single adenine residue from 
the  28S  rRNA  component  of  eukaryotic  ribosomes  [27,28].  The  B-subunit  proteins  in  the 
homopentamers  of  most  of  the  holotoxins  are  able  to  bind  to  the  neutral  glycosphingolipid 
globotriaosylceramide (Gb3; also known as Gb3Cer, CD77 or the P
k blood group antigen) on the 
surface of host cells [11,29,30]. The only exception is the receptor for a genetic variant of Stx2, called 
Stx2e  or  pig  edema  disease  toxin,  which  binds  preferentially  to  the  glycosphingolipid 
globotetraosylceramide (Gb4) [31]. 
2.2. Toxin Interaction with Cell Surface Receptors 
The trisaccharide carbohydrate structure of Gb3 has been shown to directly interact with Shiga 
toxin  B-subunits,  although  variability  in  the  lipid  moiety  of  Gb3  also  affects  toxin  binding  [32]. 
Interestingly, each B-subunit protein possesses three Gb3 binding sites, suggesting that each holotoxin 
molecule may cross-link up to 15 Gb3 molecules [33,34]. This cooperative binding may explain the 
high affinity of Shiga toxins for Gb3. Furthermore, Gb3 cross-linking may be a critical component for 
toxin mediated induction of negative membrane curvature and the initiation of toxin internalization [35]. 
Several lines of evidence established Gb3 as the receptor for Shiga toxins. The addition of Gb3 to Toxins 2010, 2                         
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culture medium inhibited the biological activity of Shiga toxins. In addition, when Gb3 receptors were 
destroyed by digestion of membrane glycosphingolipids with galactosidases, or if the synthesis of 
glycosphingolipids was blocked, toxin-mediated cytotoxicity was lost [36,37]. It is now recognized 
that Gb3 displays significant molecular heterogeneity, including differences in fatty acyl chain length, 
degree of bond saturation and hydroxylation status. The affinity of Shiga toxins for Gb3 is dependent 
on the structure of the fatty acid moiety, and hydroxylation of C22 and C18 fatty acids increased toxin 
binding  to  Gb3  [38].  Following  Gb3  binding  and  the  formation  of  toxin-containing  membrane 
invaginations,  the  invaginations  may  form  tubules  that  separate  from  the  plasma  membrane  in  a 
process called scission. Using giant unilamellar vesicles reconstituted with Gb3, Rö mer et al. [39] 
showed that α-hydroxylated Gb3 was necessary for scission. Vesicles containing non-hydroxylated 
Gb3 formed tubules which did not undergo scission. Finally, the nature of the phospholipids found in 
the surrounding membrane may also play a role in the interaction of Shiga toxins with Gb3 [40,41]. 
While the glycosphingolipid Gb3 is the major receptor responsible for toxin binding, leading to 
internalization and routing to the ER, Shiga toxins may associate with cells that lack membrane Gb3 
expression. For example, Shiga toxins associate with human intestinal epithelial cells in such a manner 
as to allow the translocation of the toxins into the lamina propria, even though the human colonic 
epithelial lining is essentially Gb3 negative [42]. Shiga toxins have also been reported to bind an, as 
yet, uncharacterized receptor on Gb3-deficient human neutrophils, albeit with a lower affinity than the 
interaction with Gb3 [9,10,43]. Shiga toxin interaction with neutrophils does not appear to trigger toxin 
internalization  or  cytotoxicity.  Numerous  histopathological  studies  in  HUS  cases  [44,45]  and  in 
animals receiving Shiga toxins [7,8], and in vitro studies [46,47], suggest that endothelial cells are the 
primary targets of the cytotoxic action of Shiga toxins. In general, cultured human endothelial cells 
express Gb3, bind Shiga toxins, and are susceptible to the cytotoxic effects of the toxins. However, 
endothelial cells derived from different tissues exhibit different susceptibilities to the toxins, and these 
differences in susceptibility may be linked with differences in Gb3 expression  [48] and structural 
heterogeneity of Shiga toxin-binding glycosphingolipids [49]. Importantly, both from the standpoint of 
studies  designed  to  explore  toxin  entry  into  cells  and  for  studies  on  the  progression  of  disease, 
expression of Gb3 on the cell surface may be regulated by many factors. Bacterial lipopolysaccharides 
(LPS), and the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin 1 (IL-1) 
have  all  been  reported  to  increase  synthesis  of  Gb3  and  exposure  of  toxin  binding  sites  at  the 
endothelial  cell  surface.  In  some  cell  types,  membrane  glycosphingolipid  composition  may  be 
regulated by butyric acid, a metabolic end-product found in the digestive tract [11,50]. 
2.3. Intracellular Trafficking of the Toxins 
Binding of the holotoxin molecule to Gb3 is a prerequisite for entry of the multi-subunit protein 
into the target cell [11]. In brief, once Shiga toxins bind Gb3, the toxins are internalized via the Golgi 
apparatus to the ER, a process referred to as retrograde transport [12]. The molecular mechanisms of 
intracellular transport of Shiga toxins have been reviewed in detail [30,51]. Also the use of the toxins 
as probes for studying intracellular transport and the B-subunit as a transporting vehicle for foreign 
proteins  into  target  cells  is  reviewed  by  Sandvig  et  al.  [51].  During  intracellular  trafficking,  the  
A-subunits of Shiga toxins are cleaved by furin, a calcium-sensitive serine protease located in the Toxins 2010, 2                         
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trans-Golgi network [52,53]. The furin-processed A-subunit, comprised of a 27 kDa A1-fragment and 
a 4 kDa A2-fragment, remains linked via a disulfide bond. Within the ER, the A1- and A2-fragments 
separate  [53].  The  A1-fragment,  containing  N-glycosidase  activity,  is  translocated  across  the  ER 
membrane to cytoplasm.  
2.3.1. Endocytosis of Shiga toxins  
After binding to Gb3, Shiga toxins may be internalized by a clathrin-independent receptor-mediated 
process or internalized from clathrin-coated pits [29,30,54]. The toxins have been shown capable of 
mediating  clathrin  phosphorylation,  which  triggers  toxin  uptake  in  some  cell  types  [55].  The 
mechanism of clathrin-independent toxin internalization remains to be clarified, although Rö mer et al. [35] 
reported  that  B-subunits  of  Shiga  toxin  induce  membrane  invaginations  with  the  development  of 
tubular connections for toxin cellular uptake. Interestingly, it was recently reported that the role of 
clathrin for endocytosis and intracellular transport of the toxins may be altered in a single cell type. 
Specifically,  butyric  acid  treatment  of  HeLa  and  BHK  cells  not  only  sensitized  the  cells  to  the 
cytotoxic action of Shiga toxins, but also increased internalization via clathrin-dependent mechanisms [56]. 
Confocal microscopy experiments revealed a higher extent of co-localization between Shiga toxins and 
clathrin after butyric acid treatment. In HeLa cells, Shiga toxin B-subunits were found to be associated 
with  detergent-resistant  membrane  microdomains  or  lipid  rafts  [57].  To  what  extent  such  an 
association  is  important  for  the  endocytic  pathway  utilized  by  the  toxins  is  not  known,  although 
macrophages, which do not coalesce Gb3 into lipid rafts, fail to route toxin B-subunits to the ER [57]. 
Thus,  after  endocytosis,  Shiga  toxins  or  toxin  B-subunits  may  be:  (i)  directly  transported  from 
early/recycled endosomes to the Golgi apparatus for further transport to the ER [58,59]; (ii) transported 
to  lysosomes  for  proteolytic  degradation  [57];  or  (iii)  transcytosed  across  polarized  epithelial 
monolayers [5,6].  
2.3.2. Endosome to Golgi Apparatus Transport of Shiga Toxins 
A critical step in the intracellular transport of Shiga toxins leading to intoxication and cell death is 
the transport of the toxins from early endosomes to the trans-Golgi network (TGN). A well-studied 
pathway leading from early endosomes to the Golgi apparatus involves transport via the late endosome 
utilizing the small GTP-binding protein Rab9. This Rab9-dependent pathway is responsible for sorting 
mannose-6-phosphate receptors (M6PR) [60–62]. This pathway is also used by furin, a protease which 
processes Shiga toxin A-subunits, that recycles between the cell surface, endosomes, and the Golgi 
apparatus [63]. In contrast to this well characterized transport process, Shiga toxins appear to utilize a 
Rab9-independent pathway for efficient transport from endosomes to the TGN using a mechanism 
dependent on functional dynamin and clathrin [12,56]. In particular, clathrin adaptor protein epsinR is 
involved in sorting from early endosomes to the trans-Golgi network (TGN) in the retrograde transport 
of  Shiga  toxins  [64].  Additional  host  proteins  involved  in  toxin  transport  to  the  Golgi  apparatus 
include: (i) Rab11 and a Rab6 isoform (Rab6a’), GTP-binding proteins which also regulate vesicular 
trafficking; (ii) v-soluble N-ethylmaleimide-sensitive factor attachment protein receptor (v-SNARE), 
described as a trans-membrane protein essential for membrane fusion [65]; and (iii) vesicle-associated 
membrane protein (VAMP) 3, and VAMP4 [66–68]. The requirement of the retromer complex in Toxins 2010, 2                         
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retrograde transport was established by using the B-subunit of Shiga toxin [69]. Recently, Bujny et al. 
[70] and Utskarpen et al. [71] defined an essential role of protein retromer component sorting nexin-1 
(SNX1) and sorting nexin-2 (SNX2) for efficient trafficking of Shiga toxin from early endosomes to 
the TGN. A complete understanding of the sorting mechanisms trafficking Shiga toxins from early 
endosomes to the Golgi apparatus is still an area of active investigation.  
2.3.3. Toxin Transport from the Trans-Golgi Network to the ER and Nuclear Envelope 
Studies  are  ongoing  to  describe  the  mechanisms  by  which  Shiga  toxins  are  transported  in  a 
retrograde manner from the TGN to the ER. Normally, host proteins may be retrieved from the Golgi 
to the ER, and retrotranslocated in the ER, if the proteins possess a KDEL sequence capable of binding 
so-called KDEL receptors in the Golgi apparatus. For bacterial toxins, such as Pseudomonas exotoxin 
A, which possess KDEL or KDEL-like sequences, transport via interaction with the KDEL-receptor in 
COP I-coated vesicles is involved in retrograde transport to the ER [72]. Despite the fact that Shiga 
toxins do not express the KDEL retrieval sequence motif, they are able to move in a retrograde manner 
from the Golgi apparatus to the ER via a COP I-independent, Rab6a’-dependent route [73,74]. Shiga 
toxin 1 has been shown to reach the nuclear envelope [41,75] and to get into the nucleus of intoxicated 
cells [76] inducing the formation of apurinic/apyrimidinic sites in nuclear DNA [77]. 
2.3.4. Transport of Shiga Toxins from the ER to the Cytosol 
The characterization of translocation mechanisms by which Shiga toxins move from the ER lumen 
into the cytosol is an area of active study. Internalization of many AB toxins, such as large clostridial 
cytotoxins, results in the formation of a channel in the endosomal membrane so that toxin enzymatic 
A-subunits may be directly delivered into the cytosol for host cell intoxication [78]. However, several 
AB5 toxins, such as Shiga toxins and cholera toxin, cannot form pores for the purpose of delivery of 
toxin A-subunits into the cytosol [79,80]. Within the ER, the Shiga toxin A1-fragment dissociates from 
the A2-fragment + B-subunits following proteolysis by furin and disulfide bond reduction [30,53]. 
Toxin mutants with deletions in the furin cleavage site are processed by a calpain-like enzyme [52,81], 
suggesting that proteases other than furin may process Shiga toxin A-subunits for retrotranslocation 
across the ER membrane. However, alternative mechanisms of A-subunit processing remain to be 
rigorously defined. Finally, several studies have shown that Shiga toxins appear to interact with ER 
lumen-resident chaperones such as HEDJ/ERdj3 [82] and BiP [83]. Interactions with chaperones may 
be  necessary  to  induce  unfolding  of  the  A1-fragment  prior  to  retrotranslocation  across  the  ER 
membrane. To date, published studies suggest that only the toxin A1-fragment is retrotranslocated into 
the cytoplasm [84].  
3. Shiga Toxins Induce the Ribotoxic Stress Response 
Despite advances in understanding toxin structure, mode of action, and molecular mechanisms of 
toxin  intracellular  transport  that  underlie  the  pathogenesis  of  diseases  caused  by  Shiga  toxins, 
investigation  of  the  action  of  the  toxins  on  the  60S  component  of  eukaryotic  ribosomes  brought 
attention  to  novel  properties  of  the  toxins  which  may  or  may  not  contribute  to  protein  synthesis Toxins 2010, 2                         
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inhibition and cytotoxicity. In 1997, Iordanov et al. [85] reported that two toxic enzymes which act on 
eukaryotic ribosomes, the plant toxic lectin ricin A-chain and the fungal ribotoxin α-sarcin, targeted 
the  peptidyl  transferase  reaction  center  of  28S  rRNA  for  inactivation  of  ribosomes  and  protein 
synthesis inhibition, and in the process, activated the stress-activated protein kinase signaling pathway 
involving c-Jun NH2-terminal kinases (JNK). Shiga toxin A1-fragments, through their N-glycosidase 
activity, remove a single adenine residue from a portion of the 28S rRNA molecule involved in the 
peptidyl transferase reaction. It was subsequently shown using human epithelial and monocytic cell 
lines [86–88] that Shiga toxin-mediated modification of the ribosome triggered not only the activation 
of the JNK pathway, but the activation of the p38 mitogen-activated protein kinase (p38 MAPK) and 
extracellular-signaling  regulated  kinase  (ERK)  pathways.  MAPK  activation  originating  from  
toxin-modified ribosomes has been termed the ribotoxic stress response [85]. Shiga toxin-mediated 
activation  of  the  ribotoxic  stress  response  in  epithelial  and  macrophage-like  cells  appears  to  be 
essential for the expression of pro-inflammatory cytokines and chemokines [86–88]. Double-stranded 
RNA-activated protein kinase R (PKR), and the upstream kinases MKK 3/6 and ZAK, participate in 
signaling  during  the  ribotoxic  stress  response  induced  by  ricin,  Shiga  toxins,  and  the  fungal 
trichothecene toxin deoxynivalenol (DON) [89,90]. The role of ribotoxic stress response in induction 
of apoptosis by Shiga toxins remains to be fully characterized. Smith et al. [87] showed that treatment 
of epithelial cells with a JNK or p38 MAPK inhibitor protected cells from cytotoxicity and reduced 
procaspase-3  activation.  JNK,  p38  and  ERK  MAPKs  also  appear  to  regulate  the  differential 
phosphorylation  of  the  anti-apoptotic  factor  Bcl-2  [91,92]  so  that  apoptosis  may  be  facilitated  or 
inhibited. Finally, protein synthesis per se does not induce the ribotoxic stress response. For example, 
cycloheximide,  a  drug  which  effectively  inhibits  protein  synthesis  in  human  monocytes,  does  not 
induce the ribotoxic stress response or induce apoptosis [93]. Thus, the mechanism by which protein 
synthesis is inhibited, i.e., acting on the peptidyl transferase center, may be essential for ribotoxic 
stress response activation.  
4. ER Stress Responses and Shiga Toxin-Induced Apoptosis 
4.1. Shiga Toxins Induce Apoptosis 
Apoptosis, or programmed cell death, is a type of cell death originally described by morphological 
changes  such  as  membrane  blebbing  (formation  of  cellular  apoptotic  bodies),  cell  shrinkage,  and 
nuclear changes including chromatin condensation and DNA fragmentation. Apoptosis is mediated by 
sequential activation of a cascade of aspartate-specific cysteine proteases, called caspases. Two major 
pathways  involved  in  the  induction  of  apoptosis  have  been  characterized:  the  intrinsic  or  
mitochondria-mediated, and the extrinsic or death receptor-mediated pathways of apoptosis induction. 
Recently,  numerous  studies  have  shown  that  Shiga  toxins  induce  apoptosis  through  different 
mechanisms in different cell types, including human epithelial cells, endothelial cells, and neurons 
(reviewed  in  [94]).  Primary  human  monocyte-derived  macrophages  appear  to  be  resistant  to 
intoxication by Shiga toxins at physiological concentrations when cultured in vitro [95]. However, 
Stx1 induces apoptosis of the human myeloid leukemia cell line THP-1 in a cell maturation-dependent 
manner  [96].  Stx1-mediated  apoptosis  of  monocytic  THP-1  cells  involved  a  novel  pathway  using Toxins 2010, 2                         
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components of both the extrinsic and intrinsic pathways of apoptosis [93]. Stx1 induced the cleavage 
of procaspase-8 to its active form caspase-8, which appeared to be an early event, leading to the direct 
activation of procaspase-3 and the generation of the activated form of the Bcl-2 family protein BID 
(truncated  BID  or  tBID).  tBID  translocated  to  the  mitochondrial  membrane  leading  to  increased 
mitochondrial membrane permeability, release of cytochrome c and formation of the apoptosome. Stx1 
enzymatic activity was required to induce apoptosis. A significant fraction of procaspase-8 is known to 
be associated with the ER membrane [97] and this ER-localized procaspase-8 may be involved in the 
early activation of caspase-8. Taken together, the data indicated that apoptosis of monocytic THP-1 
cells required the retrograde transport of functional toxin to the ER, where signaling for cell death 
through early procaspase-8 cleavage may originate.  
4.2. Shiga Toxins Induce the ER Stress Response Leading to Apoptosis  
In addition to its role in the translocation of nascent proteins into the cell secretory apparatus, the 
ER is the principal site for the correct folding of proteins. A protein ―quality control‖ process which 
monitors protein folding, and initiates a highly orchestrated series of signaling events to properly fold 
proteins,  has  been  characterized  [98,99].  Activation  of  this  ―quality  control‖  process  includes  ER 
luminal proteins called molecular chaperones. Chaperones associate with improperly folded proteins 
and may facilitate protein re-folding or retrotranslocation of mis-folded proteins into the ER-associated 
degradation (ERAD) pathway [100,101]. The rate of flux of newly synthesized proteins through the 
ER may vary based upon environmental signals, such as alterations in the ER lumen redox state, 
aberrant glycosylation, aberrant intracellular calcium homeostasis, and temperature. Thus, the capacity 
of the ER to correctly fold nascent proteins may become saturated, and this condition is referred to as 
ER stress [102,103]. The three proximal ER membrane-associated sensors of protein folding are the 
kinase PKR-like ER kinase (PERK), the kinase/endoribonuclease inositol-requiring enzyme 1 (IRE-1) 
and the transcription factor activating transcription factor-6 (ATF-6) [103]. Normally, these sensors are 
thought to be in association with the chaperone BiP. However, in the presence of improperly folded 
proteins, BiP dissociates from PERK, IRE-1 and ATF-6. PERK and IRE-1 are thought to undergo 
proximity-dependent  auto-phosphorylation,  while  ATF-6  translocates  to  the  Golgi  apparatus  and 
undergoes proteolytic processing to form an active transcription factor [103–106]. PERK-mediated 
phosphorylation of the translation initiation factor eIF2α transiently inhibits most protein translation, 
thereby reducing the flux of nascent polypeptides through the stressed ER [104]. However, ER stress 
activates genes possessing promoters with ER-stress response elements (ERSE) and unfolded protein 
response  elements  (UPRE)  [106].  The  transcriptional  activation  through  these  promoter  elements 
modulates the expression levels of ER-resident chaperones, such as BiP, involved in assisting correct 
protein folding in the ER [107]. Increased transcriptional activation is mediated, in large part, by IRE-1 
and ATF-6. The endoribonuclease function of IRE-1 cleaves the transcript for the transcription factor 
X-box protein-1 (Xbp-1), and the processed mRNA encodes a transcription factor with an altered DNA 
binding profile [108,109]. ATF-6 is cleaved by host cell proteases S1P and S2P to form an active basic 
leucine zipper transcription factor [110]. Thus, even in the face of translational inhibition, a subset of 
genes encoding proteins involved in protein folding and processing are expressed.  Toxins 2010, 2                         
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The ER stress response has been reported in be initiated in pathogen-infected cells [111,112], and 
given the capacity of Shiga toxins to inhibit protein synthesis and generate truncated or mis-folded 
proteins, one might predict that the toxins would activate the ER stress response. Lee et al. [113] 
demonstrated that Stx1 treatment of the human monocytic cell line THP-1 was capable of inducing ER 
stress and activating all three proximal ER stress sensor molecules involved in the immediate detection 
of  improperly  folded  proteins  (Figure  1).  Furthermore,  all  the  sensors  were  active  as  shown  
by  phosphorylation  of  eIF2α,  processing  of  Xbp-1  mRNA,  and  the  detection  of  ATF-6  
cleavage fragments.  
Figure 1. Model of Stx1-mediated ER stress and induction of apoptosis. Following binding 
to the membrane glycosphingolipid receptor Gb3, Stx1 is transported to the ER. The ER 
stress sensors IRE1, PERK are activated by phosphorylation (up arrows) while levels of 
unprocessed 90 kDa ATF-6 decrease (down arrow) leading to release of the active 50 kDa 
active  transcription  factor.  Signaling  through  the  ER  stress  sensors  leads  to  increased 
CHOP,  DR5  and  TRAIL  expression,  and  decreased  Bcl-2  expression.  Autocrine  or 
paracrine TRAIL–DR5 interactions may contribute to apoptosis induction. Toxin transport 
to  the  ER  is  also  associated  with  increased  cytosolic  Ca
2+  levels,  leading  to  calpain 
activation  and  cleavage  of  procaspase-8  to  produce  the  initiator  caspase  and  
activation of programmed cell death. Reproduced with permission from Wiley [113]. 
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Multiple  outcomes  may  follow  activation  of  the  ER  stress  response.  If  the  accumulation  of 
improperly folded proteins is cleared from the ER, the cell may return to normal homeostasis. If 
activation of the ER stress response fails to clear the cause of stress, apoptotic cell death may follow 
(reviewed  in  [107]).  Thus,  prolonged  signaling  through  PERK,  IRE-1  and  ATF-6  may  activate 
programmed  cell  death.  PERK-  and  ATF-6-dependent  up-regulation  of  the  gene  encoding  C/EBP 
homology  protein  (CHOP;  alternatively  referred  to  as  GADD153)  appears  essential  in  apoptosis 
induction. CHOP is a transcriptional regulator that represses the expression of anti-apoptotic factor 
Bcl-2 [107,114]. Stx1 treatment of toxin sensitive monocytic THP-1 cells led to increased CHOP 
expression  and  decreased  Bcl-2  expression  (Figure  1)  [113].  In  agreement  with  earlier  studies 
characterizing  signaling  mechanisms  activated  by  ER  stress  leading  to  apoptosis  [115,116],  
Stx1-induced  up-regulation  of  CHOP  also  increased  the  expression  of  the  apoptosis  ligand-death 
receptor pair TNF-α-related apoptosis inducing ligand (TRAIL) and death-domain containing receptor 5 
(DR5, also referred to as TRAIL-R2) [113]. Thus, monocytic THP-1 cells intoxicated with Shiga 
toxins appear incapable of alleviating ER stress leading to apoptosis. 
Shiga  toxins  are  not  the  only  microbial  toxins  that  may  induce  apoptosis  through  prolonged 
activation of the ER stress response. It has recently been shown that subtilase cytotoxin, a new member 
of  the  AB5  toxin  family  which  is  secreted  by  some  STEC,  cleaves  the  chaperone  BiP,  thereby 
triggering the ER stress response resulting in cytotoxicity [117,118]. Subtilase cytotoxin activates all 
the proximal sensors of ER stress [118]. Deoxynivalenol, a trichothecene mycotoxin produced by 
Fusarium sp., also triggers the ER stress response via IRE1, XBP-1 and ATF-6 activation and causes 
degradation of BiP in murine peritoneal macrophages [119]. 
4.3. Calcium Involvement in Shiga Toxin-Induced Apoptosis 
The role of calcium (Ca
2+) influx from extracellular sources or efflux from intracellular stores in the 
decision to commit to apoptosis or cell survival in response to extracellular stress has been explored 
for more than two decades [120,121]. In response to ER stress, Ca
2+ in intracellular stores may be 
released into the cytoplasm from the ER. Bax and Bak, Bcl-2 protein family members containing BH3 
domains, are ER membrane localized and participate in rapid Ca
2+ efflux. Ca
2+ may then be taken up 
by  mitochondria  or  may  directly  activate  the  calcium-dependent  proteases  called  calpains.  The 
translocation  of  Bax  and  Bak  to  mitochondrial  membranes  may  lead  to  increased  membrane 
permeability and generation of the apoptosome, and calpains may directly activate caspases. Thus, 
changes in intracellular Ca
2+ localization may contribute to the induction of apoptosis [122–124]. Stx1 
perturbs normal intracellular Ca
2+ homeostasis by triggering Ca
2+ release from ER stores into the 
cytoplasm in THP-1 cells [113,125]. Cherla et al. [125] showed that Stx1 activated PI3K, which may 
trigger generation of phospholipid second messengers and release of Ca
2+ from intracellular stores in 
macrophage-like THP-1 cells. However, our understanding of the role of intracellular Ca
2+ flux and 
Ca
2+-activated regulatory components in apoptosis induction in Shiga toxin-stressed cells will require 
further studies.  Toxins 2010, 2                         
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5. Shiga Toxin-Induced ER Stress: The Cell Death vs. Survival Decision 
Relatively  little  is  known  about  the  regulatory  mechanisms  by  which  host  cells  alter  signaling 
pathways in response to Shiga toxins to induce apoptosis or favor cell survival. As noted earlier, 
sensitivity of the THP-1 cell line to the cytotoxic action of Shiga toxins is cell maturation-dependent 
[96].  Undifferentiated,  monocytic  THP-1  cells  are  sensitive  to  killing  by  purified  Stx1,  while 
differentiated, macrophage-like THP-1 cells are relatively refractory to the cytotoxic action of the 
toxin, with only approximately 30% of cells undergoing apoptosis. Interestingly, apoptotic signaling 
pathways were activated by Shiga toxins in both cell types, suggesting that compensatory cell survival 
signaling pathways may be triggered in mature, macrophage-like cells, but not in monocytic cells 
[126,127]. In studies designed to explore apoptotic and cell survival signaling pathways triggered by 
Stx1 in THP-1 cells, differences in activation of the ER stress response were noted. Specifically, Stx1 
activated the proximal ER stress sensors PERK and IRE-1, but failed to mediate ATF-6 proteolysis in 
macrophage-like cells [127]. Thus, one of the main regulators of CHOP expression was not activated 
in Stx1 treated macrophage-like THP-1 cells. Pro-apoptotic signaling pathways, including increased 
TRAIL and DR5 expression, and release of Ca
2+ from intracellular stores and calpain activation, which 
were initially characterized in the toxin sensitive monocytic cell, were also activated in toxin resistant 
macrophage-like THP-1 cells. However, compensatory pro-survival signaling mechanisms appeared to 
be selectively activated in macrophage-like cells. In specific, expression levels of the pro-survival 
factor  Bcl-2  were  increased,  Bcl-2  readily  translocated  to  the  mitochondria,  and  Bcl-2  was 
phosphorylated at serine residues which facilitate pro-survival functions of Bcl-2 [127]. Thus, as has 
been reported earlier [128,129], the balance between cell death and survival signaling appears to be 
regulated by the interplay with pro-apoptotic factors, such as Bax/Bak, with pro-survival factors such 
as  Bcl-2  and  Bcl-xL.  To  explore  the  mechanisms  of  apoptosis  induction  in  the  subset  of  
macrophage-like THP-1 cells that die in response to Stx1, we utilized RNA interference technology to 
knock-down  DR5  and  CHOP  expression  levels.  The  data  indicated  that  silencing  these  pathways 
significantly protected cells against Stx1 treatment in differentiated macrophage-like cells, but not 
monocytic cells, suggesting that the TRAIL-DR5 pathway may be relatively more important in killing 
differentiated cells [130]. We also noted differences in the kinetics of calpain activation in Stx1-treated 
undifferentiated  and  differentiated  cells.  Calpain  activation  occurred  rapidly  after  intoxication  in 
undifferentiated  monocytic  cells,  suggesting  that  Ca
2+-dependent  signaling  may  account  for  the 
heightened toxin sensitivity. 
6. Conclusions  
Structures of Shiga toxins, toxin enzymatic activity, and toxin intracellular trafficking have been 
defined. However, only limited studies have been published on the host cellular responses triggered or 
regulated during Shiga toxin binding, internalization and trafficking. Following interaction with the 
toxin-binding glycosphingolipid Gb3, Shiga toxins are internalized, trafficked into and through the 
Golgi apparatus in a retrograde manner to reach the lumen of the ER. From the ER, a proteolytically 
processed fragment of the toxin A-subunit enters the host cell cytosol and catalytically cleaves single 
adenine residues from the 28S rRNA component of ribosomes. This enzymatic activity, in addition to 
mediating host cellular protein synthesis inhibition, also activates the ribotoxic stress response and the Toxins 2010, 2                         
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ER stress response. The capacity of Shiga toxins to induce prolonged signaling through the ER stress 
response may lead to apoptosis. Apoptotic pathways activated by Shiga toxins include components of 
the intrinsic (mitochondria-mediated) and extrinsic (DR5-TRAIL system) pathways. However, Shiga 
toxins  may  also  activate  cell  survival  pathways,  primarily  through  mechanisms  involving  the  
pro-survival  Bcl-2  proteins.  Taken  together,  perturbing  the  intracellular  homeostasis  between  
pro-apoptotic  and  pro-survival  signaling  molecules  represents  a  critical  determinant  in  the  cell 
death/cell survival decision following intoxication with Shiga toxins. An improved understanding of 
host cell responses to the toxins will be necessary to develop therapeutic strategies to intervene in 
disease progression caused by the toxins.  
Acknowledgements 
This work was supported by U.S. Public Health Service grant 5RO1 AI34530 from the National 
Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. 
References 
1.  Proulx,  F.;  Tesh.  V.L.  Renal  diseases  in  the  Pediatric  Intensive  Care  Unit:  Thrombotic 
microangiopathy,  hemolytic  uremic  syndrome,  and  thrombotic  thrombocytopenic  purpura.  In 
Pediatric Critical Care Medicine: Basic Science and Clinical Evidence; Wheeler, D.S., Wong, 
H.R., Shanley, T.P., Eds.; Springer Verlag: London, UK, 2007; pp. 1189–1204.  
2.  Scheiring,  J.;  Andreoli,  S.P.;  Zimmerhackl,  L.B.  Treatment  and  outcome  of  Shiga-toxin-
associated hemolytic uremic syndrome (HUS). Pediatr. Nephrol. 2008, 23, 1749–1760. 
3.  Karch, H.; Tarr, P.I.; Bielaszewska, M. Enterohaemorrhagic Escherichia coli in human medicine. 
Int. J. Med. Microbiol. 2005, 295, 405–418. 
4.  Bale, J.F.; Brasher, C.; Siegler, R.L. CNS manifestations of the hemolytic-uremic syndrome. 
Relationship to metabolic alterations and prognosis. Am. J. Dis. Child. 1980, 134, 869–872. 
5.  Hurley, B.P.; Jacewicz, M.; Thorpe, C.M.; Lincicome, L.L.; King, A.J.; Keusch, G.T.; Acheson, 
D.W.K. Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. 
Infect. Immun. 1999, 67, 6670–6677. 
6.  Malyukova, I.; Murray, K.F.; Zhu, C.; Boedeker, E.; Kane, A.; Patterson, K.; Peterson, J.R.; 
Donowitz, M.; Kovbasnjuk, O. Macropinocytosis in Shiga toxin 1 uptake by human intestinal 
epithelial cells and transcellular transcytosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 
296, G78–G92. 
7.  Fontaine, A.; Arondel, J.; Sansonetti, P.J. Role of Shiga toxin in the pathogenesis of bacillary 
dysentery, studied by using a Tox
− mutant of Shigella dysenteriae 1. Infect. Immun. 1988, 56, 
3099–3109. 
8.  Taylor,  F.B.;  Tesh,  V.L.;  DeBault,  L.;  Li,  A.;  Chang,  A.C.K.;  Kosanke,  S.D.;  Pysher,  T.J.; 
Siegler, R.L. Characterization of the baboon responses to Shiga-like toxin: Descriptive study of a 
new primate model of toxic responses to Stx-1. Am. J. Path. 1999, 154, 1285–1299. Toxins 2010, 2                         
 
 
1527 
9.  te Loo, D.M.W.M.; Monnens, L.A.H.; van der Velden, T.J.A.N.; Vermeer, M.A.; Preyers, F.; 
Demacker, P.N.M.; van den Heuvel, L.P.W.J.; van Hinsbergh, V.W.M. Binding and transfer of 
verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000, 95, 
3396–3402. 
10.  Brigotti, M.; Carnicelli, D.; Ravanelli, E.; Barbieri, S.; Ricci, F.; Bontadini, A.; Tozzi, A.E.; 
Scavia,  G.;  Caprioli,  A.;  Tazzari,  P.L.  Interactions  between  Shiga  toxins  and  human 
polymorphonuclear leukocytes. J. Leukoc. Biol. 2008, 84, 1019–1027. 
11.  Lingwood, C.A. Shiga toxin receptor glycolipid binding. Pathology and utility. In Methods in 
Molecular Medicine. E. coli Shiga Toxin Methods and Protocols; Philpott, D., Ebel. F., Eds.; 
Humana Press, Inc.: Totowa, NJ, USA, 2003; Volume 73, pp. 165–186. 
12.  Sandvig, K.; Grimmer, S.; Lauvrak, S.U.; Torgersen, M.L.; Skretting, G.; van Deurs, B.; Iversen, 
T.G. Pathways followed by ricin and Shiga toxin into cells. Histochem. Cell Biol. 2002, 117, 
131–141. 
13.  Johannes, L.; Rö mer, W. Shiga toxins—From cell biology to biomedical applications. Nat. Rev. 
Microbiol. 2010, 8, 105–116. 
14.  Armstrong,  G.D.;  Fodor,  E.;  Vanmaele,  R.  Investigation  of  Shiga-like  toxin  binding  to 
chemically synthesized oligosaccharide sequences. J. Infect. Dis. 1991, 164, 1160–1167. 
15.  Armstrong,  G.D.;  McLaine,  P.N.;  Rowe,  P.C.  Clinical  trials  of  Synsorb-Pk  in  preventing 
hemolytic-uremic syndrome. In Escherichia coli O157:H7 and Other Shiga toxin-producing E. 
coli  Strains;  Kaper,  J.B.,  O'Brien,  A.D.,  Eds.;  ASM  Press:  Washington,  DC,  USA,  1998;  
pp. 374–384.  
16.  Trachtman,  H.;  Cnaan,  A.;  Christen,  E.;  Gibbs,  K.;  Zhao,  S.;  Acheson,  D.W.K.;  Weiss,  R.; 
Kaskel,  F.J.;  Spitzer,  A.;  Hirschman,  G.H.  Effect  of  an  oral  Shiga  toxin–binding  agent  on 
diarrhea-associated  Hemolytic  Uremic  Syndrome  in  children:  A  randomized  controlled  trial. 
JAMA 2003, 290, 1337–1344. 
17.  Nishikawa, K.; Matsuoka, K.; Kita, E.; Okabe, N.; Mizuguchi, M.; Hino, K.; Miyazawa, S.; 
Yamasaki, C.; Aoki, J.; Takashima, S.; Yamakawa, Y.; Nishijima, M.; Terunuma, D.; Kuzuhara, 
H.; Natori, Y. A therapeutic agent with oriented carbohydrates for treatment of infections by 
Shiga  toxin-producing  Escherichia  coli  O157:H7.  Proc.  Natl.  Acad.  Sci.  USA  2002,  99,  
7669–7674. 
18.  Saenz, J.B.; Doggett, T.A.; Haslam, D.B. Identification and characterization of small molecules 
that inhibit intracellular toxin transport. Infect. Immun. 2007, 75, 4552–4561. 
19.  Mukherjee, J.; Chios, K.; Fishwild, D.; Hudson, D.; O’Donnell, S.; Rich, S.M.; Donohue-Rolfe, 
A.; Tzipori, S. Production and characterization of protective human antibodies against Shiga 
toxin 1. Infect. Immun. 2002, 70, 5896–5899. 
20.  Pinyon, R.A.; Paton, J.C.; Paton, A.W.; Botten, J.A.; Morona, R. Refinement of a therapeutic 
Shiga toxin—Binding probiotic for human trials. J. Infect. Dis. 2004, 189, 1547–1555. 
21.  Strockbine, N.A.; Marques, L.R.M.; Newland, J.W.; Williams-Smith, H.; Holmes, R.K.; O'Brien, 
A.D.  Two  toxin-converting  phages  from  Escherichia  coli  O157:H7  strain  933  encode 
antigenically distinct toxins with similar biologic activities. Infect. Immun. 1986, 53, 135–140. Toxins 2010, 2                         
 
 
1528 
22.  Mellmann,  A.;  Bielaszewska,  M.;  Kock,  R.;  Friedrich,  A.W.;  Fruth,  A.;  Middendorf,  B.; 
Harmsen, D.; Schmidt, M.A.; Karch, H. Analysis of collection of hemolytic uremic syndrome-
associated enterohemorrhagic Escherichia coli. Emerg. Infect. Dis. 2008, 14, 1287–1290. 
23.  Jackson, M. P.; Newland, J.W.; Holmes, R.K.; O'Brien, A.D. Nucleotide sequence analysis of the 
structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. 
Microb. Pathog. 1987, 2, 147–153. 
24.  Stein,  P.E.;  Boodhoo,  A.;  Tyrrell,  G.J.;  Brunton,  J.L.;  Read,  R.J.  Crystal  structure  of  the  
cell-binding B oligomer of verotoxin-1 from E. coli. Nature 1992, 355, 748–750. 
25.  Fraser, M.E.; Chernaia, M.M.; Kozlov, Y.V.; James, M.N.G. Crystal structure of the holotoxin 
from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1994, 1, 59–64. 
26.  Fraser, M.E.; Fujinaga, M.; Cherney, M.M.; Melton-Celsa, A.R.; Twiddy, E.M.; O'Brien, A.D.; 
James, M.N.G. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. 
Chem. 2004, 279, 27511–27517. 
27.  Endo, Y.; Tsurugi, K.; Yutsudo, T.; Takeda, Y.; Ogasawara, T.; Igarashi, K. Site of action of a 
Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. 
RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171, 45–50. 
28.  Saxena, S.K.; O'Brien, A.D.; Ackerman, E.J. Shiga toxin, Shiga-like toxin II variant, and ricin 
are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes.  
J. Biol. Chem. 1989, 264, 596–601. 
29.  Sandvig, K.; Olsnes, S.; Brown, J.E.; Petersen, O.W.; van Deurs, B. Endocytosis from coated pits 
of Shiga toxin: A glycolipid-binding protein from Shigella dysenteriae 1. J. Cell Biol. 1989, 108, 
1331–1343. 
30.  Sandvig, K.; Bergan, J.; Dyve, A.-B.; Skotland, T.; Torgersen, M.L. Endocytosis and retrograde 
transport of Shiga toxin. Toxicon 2009, doi 10.1016/j.toxicon.2009.11.021. 
31.  DeGrandis,  S.;  Law,  H.;  Brunton,  J.;  Gyles,  C.;  Lingwood,  C.A.  Globotetraosylceramide  is 
recognized by the pig edema disease toxin. J. Biol. Chem. 1989, 264, 12520–12525. 
32.  Schweppe, C.H.; Bielaszewska, M.; Pohlentz, G.; Friedrich, A.W.; Bü ntemeyer, H.; Schmidt, 
M.A.;  Kim,  K.S.;  Peter-Katalinić,  J.;  Karch,  H.;  Müthing,  J.  Glycosphingolipids  in  vascular 
endothelial  cells:  Relationship  of  heterogeneity  in  Gb3Cer/CD77  receptor  expression  with 
differential Shiga toxin 1 cytotoxicity. Glycoconj. J. 2008, 25, 291–304. 
33.  Ling, H.; Boodhoo, A.; Hazes, B.; Cummings, M.D.; Armstrong, G.D.; Brunton, J.L.; Read, R.J. 
Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. 
Biochemistry 1998, 37, 1777–1788. 
34.  Bast,  D.J.;  Banerjee,  L.;  Clark,  C.;  Read,  R.J.;  Brunton,  J.L.  The  identification  of  three 
biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit. 
Mol. Microbiol. 1999, 32, 953–960. 
35.  Rö mer,  W.;  Berland,  L.;  Chambon,  V.;  Gaus,  K.;  Windschiegl,  B.;  Tenza,  D.;  Aly,  M.R.;  
Fraisier, V.; Florent, J.C.; Perrais, D.; Lamaze, C.; Raposo, G.; Steinem, C.; Sens, P.; Bassereau, 
P.; Johannes, L. Shiga toxin induces tubular membrane invaginations for its uptake into cells. 
Nature 2007, 450, 670–675. Toxins 2010, 2                         
 
 
1529 
36.  Okuda, T.; Tokuda, N.; Numata, S.; Ito, M.; Ohta, M.; Kawamura, K.; Wiels, J.; Urano, T.; 
Tajima,  O.;  Furukawa,  K.  Targeted  disruption  of  Gb3/CD77  synthase  gene  resulted  in  the 
complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J. Biol. 
Chem. 2006, 281, 10230–10235. 
37.  Saelinger,  C.B.  Receptors  for  bacterial  toxins.  In  Bacterial  Protein  Toxins;  Burns,  D.L.,  
Barbieri, J.T., Iglewski, B.H., Rappuoli, R., Eds.; ASM Press: Washington, DC, USA, 2003;  
pp. 131–148. 
38.  Binnington, B.; Lingwood, D.; Nutikka, A.; Lingwood, C.A. Effect of globotriaosyl ceramide 
fatty acid alpha-hydroxylation on the binding by verotoxin 1 and verotoxin 2. Neurochem. Res. 
2002, 27, 807–813. 
39.  Rö mer,  W.;  Pontani,  L.L.;  Sorre,  B.;  Rentero,  C.;  Berland,  L.;  Chambon,  V.;  Lamaze,  C.; 
Bassereau, P.; Sykes, C.; Gaus, K.; Johannes, L. Actin dynamics drive membrane reorganization 
and scission in clathrin-independent endocytosis. Cell 2010, 140, 540–553. 
40.  Arab,  S.;  Lingwood,  C.A.  Influence  of  phospholipid  chain  length  on  verotoxin/globotriaosyl 
ceramide binding in model membranes: comparison of a supported bilayer film and liposomes. 
Glycoconj. J. 1996, 13, 159–166. 
41.  Arab, S.; Lingwood, C.A. Intracellular targeting of the endoplasmic reticulum/nuclear envelope 
by  retrograde  transport  may  determine  cell  hypersensitivity  to  verotoxin  via  globotriaosyl 
ceramide fatty acid isoform traffic. J. Cell. Physiol. 1998, 177, 646–660. 
42.  Schü ller, S.; Frankel, G.; Phillips, A.D. Interaction of Shiga toxin from Escherichia coli with 
human  intestinal  epithelial  cell  lines  and  explants:  Stx2  induces  epithelial  damage  in  organ 
culture. Cell. Microbiol. 2004, 6, 289–301. 
43.  Griener, T.P.; Mulvey, G.L.; Marcato, P.; Armstrong, G.D. Differential binding of Shiga toxin 2 
to human and murine neutrophils. J. Med. Microbiol. 2007, 56, 1423–1430. 
44.  Richardson, S.E.; Karmali, M.A.; Becker, L.E.; Smith, C.R. The histopathology of the hemolytic 
uremic  syndrome  associated  with  verocytotoxin-producing  Escherichia  coli  infections.  Hum. 
Pathol. 1988, 19, 1102–1108. 
45.  Habib, R. Pathology of the hemolytic uremic syndrome. In Hemolytic Uremic Syndrome and 
Thrombotic  Thrombocytopenic  Purpura;  Kaplan,  B.S.,  Trompeter,  R.S.,  Moake,  J.L.,  Eds.; 
Decker: New York, NY, USA, 1992; pp. 315–353. 
46.  Obrig,  T.G.;  Del  Vecchio,  P.J.;  Brown,  J.E.;  Moran,  T.P.;  Rowland,  B.M.;  Judge,  T.K.; 
Rothman,  S.W.  Direct  cytotoxic  action  of  Shiga  toxin  on  human  vascular  endothelial  cells. 
Infect. Immun. 1988, 56, 2373–2378. 
47.  Fujii,  J.;  Wood,  K.;  Matsuda,  F.;  Carneiro-Filho,  B.A.;  Schlegel,  K.H.;  Yutsudo,  T.;  
Binnington-Boyd,  B.;  Lingwood,  C.A.;  Obata,  F.;  Kim,  K.S.;  Yoshida,  S.;  Obrig,  T.  Shiga  
toxin 2 causes apoptosis in human brain microvascular endothelial cells via C/EBP homologous 
protein. Infect. Immun. 2008, 76, 3679–3689. 
48.  Obrig,  T.G.;  Louise,  C.B.;  Lingwood,  C.A.;  Boyd,  B.;  Barley-Maloney,  L.;  Daniel,  T.O. 
Endothelial heterogeneity  in  Shiga  toxin  receptors  and  responses.  J.  Biol.  Chem.  1993,  268, 
15484–15488. 
49.  Mü thing,  J.;  Schweppe,  C.H.;  Karch,  H.;  Friedrich,  A.W.  Shiga  toxins,  glycosphingolipid 
diversity, and endothelial cell injury. Thromb. Haemost. 2009, 101, 252–264. Toxins 2010, 2                         
 
 
1530 
50.  Sandvig, K. Shiga toxins. Toxicon 2001, 39, 1629–1635. 
51.  Sandvig, K.; Torgersen, M.L.; Engedal, N.; Skotland, T.; Iversen, T.G. Protein toxins from plants 
and  bacteria:  Probes  for  intracellular  transport  and  tools  in  medicine.  FEBS  Lett.  2010, 
doi:10.1016/j.febslet.2010.04.008. 
52.  Garred, Ø.; Dubinina, E.; Holm, P.K.; Olsnes, S.; van Deurs, B.; Kozlov, J.V.; Sandvig, K.  
Role  of  processing  and  intracellular  transport  for  optimal  toxicity  of  Shiga  toxin  and  toxin 
mutants. Exp. Cell Res. 1995, 218, 39–49. 
53.  Garred, Ø.; van Deurs, B.; Sandvig, K. Furin-induced cleavage and activation of Shiga toxin.  
J. Biol. Chem. 1995, 270, 10817–10821. 
54.  Sandvig, K.; Prydz, K.; Ryd, M.; van Deurs, B. Endocytosis and intracellular transport of the 
glycolipid-binding  ligand  Shiga  toxin  in  polarized  MDCK  cells.  J.  Cell  Biol.  1991,  113,  
553–562. 
55.  Lauvrak,  S.U.;  Wä lchli,  S.;  Iversen,  T.G.;  Slagsvold,  H.H.;  Torgersen,  M.L.;  Spilsberg,  B.; 
Sandvig, K. Shiga toxin regulates its entry in a Syk-dependent manner. Mol. Biol. Cell 2006, 17, 
1096–1109. 
56.  Lauvrak, S.U.; Torgersen, M.L.; Sandvig, K. Efficient endosome-to-Golgi transport of Shiga 
toxin is dependent on dynamin and clathrin. J. Cell Sci. 2004, 117, 2321–2331. 
57.  Falguiè res,  T.;  Mallard,  F.;  Baron,  C.;  Hanau,  D.;  Lingwood,  C.;  Goud,  B.;  Salamero,  J.; 
Johannes, L. Targeting of Shiga toxin B-subunit to retrograde transport route in association with 
detergent-resistant membranes. Mol. Biol. Cell 2001, 12, 2453–2468. 
58.  Mallard, F.; Antony, C.; Tenza, D.; Salamero, J.; Goud, B.; Johannes, L. Direct pathway from 
early/recycling  endosomes  to  the  Golgi  apparatus  revealed  through  the  study  of  Shiga  toxin  
B-fragment transport. J. Cell Biol. 1998, 143, 973–990. 
59.  Natarajan, R.; Linstedt, A.D. A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. 
Mol. Biol. Cell 2004, 15, 4798–4806. 
60.  Lombardi,  P.;  Mulder,  M.;  van  der  Boom,  H.;  Frants,  R.R.;  Havekes,  L.M.  Inefficient 
degradation of triglyceride-rich lipoprotein by HepG2 cells is due to a retarded transport to the 
lysosomal compartment. J. Biol. Chem. 1993, 268, 26113–26119. 
61.  Riederer, M.A.; Soldati, T.; Shapiro, A.D.; Lin, J.; Pfeffer, S.R. Lysosome biogenesis requires 
Rab9 function and receptor recycling from endosomes to the trans-Golgi network. J. Cell Biol. 
1994, 125, 573–582. 
62.  Miwako, I.; Yamamoto, A.; Kitamura, T.; Nagayama, K.; Ohashi, M. Cholesterol requirement 
for cation-independent mannose 6-phosphate receptor exit from multivesicular late endosomes to 
the Golgi. J. Cell Sci. 2001, 114, 1765–1776. 
63.  Sandvig, K. Transport of toxins across intracellular membranes. In  Bacterial Protein Toxins; 
Burns, D.L., Barbieri, J.T., Iglewski, B.H., Rappuoli, R., Eds.; ASM Press: Washington, DC, 
USA, 2003; pp. 157–172. 
64.  Saint-Pol, A.; Yelamos, B.; Amessou, M.; Mills, I.G.; Dugast, M.; Tenza, D.; Schu, P.; Antony, 
C.; McMahon, H.T.; Lamaze, C.; Johannes, L. Clathrin adaptor epsinR is required for retrograde 
sorting on early endosomal membranes. Dev. Cell 2004, 6, 525–538. 
65.  Chen, Y.A.; Scheller, R.H. SNARE-mediated membrane fusion. Nat. Rev. Mol. Cell Biol. 2001, 
2, 98–106. Toxins 2010, 2                         
 
 
1531 
66.  Johannes, L.; Goud, B. Facing inward from compartment shores: How many pathways were we 
looking for? Traffic 2000, 1, 119–123. 
67.  Del Nery, E.; Miserey-Lenkei, S.; Falguiè res, T.; Nizak, C.; Johannes, L.; Perez, F.; Goud, B. 
Rab6A and Rab6A' GTPases play non-overlapping roles in membrane trafficking. Traffic 2006, 
7, 394–407. 
68.  Mallard, F.; Tang, B.L.; Galli, T.; Tenza, D.; Saint-Pol, A.; Yue, X.; Antony, C.; Hong, W.; 
Goud,  B.;  Johannes,  L.  Early/recycling  endosomes-to-TGN  transport  involves  two  SNARE 
complexes and a Rab6 isoform. J. Cell Biol. 2002, 156, 653–664. 
69.  Popoff, V.; Mardones, G.A.; Tenza, D.; Rojas, R.; Lamaze, C.; Bonifacino, J.S.; Raposo, G.; 
Johannes, L. The retromer complex and clathrin define an early endosomal retrograde exit site.  
J. Cell Sci. 2007, 120, 2022–2031. 
70.  Bujny, M.V.; Popoff, V.; Johannes, L.; Cullen, P.J. The retromer component sorting nexin-1 is 
required for efficient retrograde transport of Shiga toxin from early endosome to the trans Golgi 
network. J. Cell Sci. 2007, 120, 2010–2021. 
71.  Utskarpen,  A.;  Slagsvold,  H.H.;  Dyve,  A.B.;  Skanland,  S.S.;  Sandvig,  K.  SNX1  and  SNX2 
mediate  retrograde  transport  of  Shiga  toxin.  Biochem.  Biophys.  Res.  Commun.  2007,  358,  
566–570. 
72.  Jackson, M.E.; Simpson, J.C.; Girod, A.; Pepperkok, R.; Roberts, L.M.; Lord, J.M. The KDEL 
retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during 
retrograde transport from the Golgi complex to the endoplasmic reticulum. J. Cell Sci. 1999, 112, 
467–475. 
73.  White, J.; Johannes, L.; Mallard, F.; Girod, A.; Grill, S.; Reinsch, S.; Keller, P.; Tzschaschel, B.; 
Echard, A.; Goud, B.; Stelzer, E.H. Rab6 coordinates a novel Golgi to ER retrograde transport 
pathway in live cells. J. Cell Biol. 1999, 147, 743–760. 
74.  Girod,  A.;  Storrie,  B.;  Simpson,  J.C.;  Johannes,  L.;  Goud,  B.;  Roberts,  L.M.;  Lord,  J.M.;  
Nilsson, T.; Pepperkok, R. Evidence for a COP-I-independent transport route from the Golgi 
complex to the endoplasmic reticulum. Nat. Cell Biol. 1999, 1, 423–430. 
75.  Sandvig,  K.;  Garred,  Ø.;  Prydz,  K.;  Kozlov,  J.V.;  Hansen,  S.H.;  van  Deurs,  B.  Retrograde 
transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992, 358, 510–512. 
76.  Suzuki, A.; Doi, H.; Matsuzawa, F.; Aikawa, S.; Takiguchi, K.; Kawano, H.; Hayashida, M.; 
Ohno,  S.  Bcl-2  antiapoptotic  protein  mediates  verotoxin  II–induced  cell  death:  possible 
association  between  Bcl-2  and  tissue  failure  by  E.  coli  O157:H7.  Genes  Dev.  2000,  14,  
1734–1740. 
77.  Brigotti, M.; Alfieri, R.; Sestili, P.; Bonelli, M.; Petronini, P.G.; Guidarelli, A.; Barbieri, L.; 
Stirpe, F.; Sperti, S. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human 
endothelial cells. FASEB J. 2002, 16, 365–372. 
78.  Schiavo, G.; van der Goot, F.G. The bacterial toxin toolkit. Nat. Rev. Mol. Cell Biol. 2001, 2, 
530–537. 
79.  Roy, C.R. Exploitation of the endoplasmic reticulum by bacterial pathogens. Trends Microbiol. 
2002, 10, 418–424. 
80.  Wernick,  N.L.B.;  Chinnapen,  D.J.-F;  Cho,  J.A.;  Lencer,  W.I.  Cholera  toxin:  an  intracellular 
journey into the cytosol by way of the endoplasmic reticulum. Toxins 2010, 2, 310–325. Toxins 2010, 2                         
 
 
1532 
81.  Kurmanova, A.; Llorente, A.; Polesskaya, A.; Garred, Ø.; Olsnes, S.; Kozlov, J.; Sandvig, K. 
Structural  requirements  for  furin-induced  cleavage  and  activation  of  Shiga  toxin.  Biochem. 
Biophys. Res. Commun. 2007, 357, 144–149. 
82.  Yu,  M.;  Haslam,  D.B.  Shiga  toxin  is  transported  from  the  endoplasmic  reticulum  following 
interaction with the luminal chaperone HEDJ/ERdj3. Infect. Immun. 2005, 73, 2524–2532. 
83.  Falguiè res, T.; Johannes, L. Shiga toxin B-subunit binds to the chaperone BiP and the nucleolar 
protein B23. Biol. Cell 2006, 98, 125–134. 
84.  Tam, P.J.; Lingwood, C.A. Membrane cytosolic translocation of verotoxin A1 subunit in target 
cells. Microbiology 2007, 153, 2700–2710. 
85.  Iordanov, M.S.; Pribnow, D.; Magun, J.L.; Dinh, T.-H.; Pearson, J.A.; Chen, S.L.; Magun, B.E. 
Ribotoxic stress response: Activation of the stress-activated protein kinase JNK1 by inhibitors of 
the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin 
loop in the 28S rRNA. Mol. Cell. Biol. 1997, 17, 3373–3381. 
86.  Cherla, R.P.; Lee, S.-Y.; Mees, P.L.; Tesh, V.L. Shiga toxin 1-induced cytokine production is 
mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like 
THP-1 cell line. J. Leukoc. Biol. 2006, 79, 397–407. 
87.  Smith,  W.E.;  Kane,  A.V.;  Campbell,  S.T.;  Acheson,  D.W.K.;  Cochran,  B.H.;  Thorpe,  C.M. 
Shiga  toxin  1  triggers  a  ribotoxic  stress  response  leading  to  p38  and  JNK  activation  and 
induction of apoptosis in intestinal epithelial cells. Infect. Immun. 2003, 71, 1497–1504. 
88.  Foster, G.H.; Tesh, V.L. Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and 
p38  in  the  human  monocytic  cell  line  THP-1:  Possible  involvement  in  the  production  of  
TNF-alpha. J. Leukoc. Biol .2002, 71, 107–114. 
89.  Zhou, H.R.; Lau, A.S.; Pestka, J.J. Role of double-stranded RNA-activated protein kinase R 
(PKR) in deoxynivalenol-induced ribotoxic stress response. Toxicol. Sci. 2003, 74, 335–344. 
90.  Jandhyala, D.M.; Ahluwalia, A.; Obrig, T.; Thorpe, C.M. ZAK: A MAP3Kinase that transduces 
Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell. Microbiol. 2008, 10, 
1468–1477. 
91.  Deng,  X.;  Xiao,  L.;  Lang,  W.;  Gao,  F.;  Ruvolo,  P.;  May,  W.S.  Novel  role  for  JNK  as  a  
stress-activated Bcl2 kinase. J. Biol. Chem. 2001, 276, 23681–23688. 
92.  De Chiara, G.; Marcocci, M.E.; Torcia, M.; Lucibello, M.; Rosini, P.; Bonini, P.; Higashimoto, 
Y.; Damonte, G.; Armirotti, A.; Amodei, S.; Palamara, A.T.; Russo, T.; Garaci, E.; Cozzolino, F. 
Bcl-2 Phosphorylation by p38 MAPK: Identification of target sites and biologic consequences.  
J. Biol. Chem. 2006, 281, 21353–21361. 
93.  Lee, S.-Y.; Cherla, R.P.; Caliskan, I.; Tesh, V.L. Shiga toxin 1 induces apoptosis in the human 
myelogenous  leukemia  cell  line  THP-1  by  a  caspase-8-dependent,  tumor  necrosis  factor  
receptor-independent mechanism. Infect. Immun. 2005, 73, 5115–5126. 
94.  Tesh, V.L. Induction of apoptosis by Shiga toxins. Future Microbiol. 2010, 5, 431–453. 
95.  Cameron,  P.;  Smith,  S.J.;  Giembycz,  M.A.;  Rotondo,  D.;  Plevin,  R.  Verotoxin  activates  
mitogen-activated protein kinase in human peripheral blood monocytes: role in apoptosis and 
proinflammatory cytokine release. Br. J. Pharmacol. 2003, 140, 1320–1330. Toxins 2010, 2                         
 
 
1533 
96.  Harrison, L.M.; Cherla, R.P.; van den Hoogen, C.; van Haaften, W.C.E.; Lee, S.-Y.; Tesh, V.L. 
Comparative evaluation of apoptosis induced by Shiga toxin 1 and/or lipopolysaccharides in 
human monocytic and macrophage-like cells. Microb. Pathog. 2005, 38, 63–76. 
97.  Jimbo, A.; Fujita, E.; Kouroku, Y.; Ohnishi, J.; Inohara, N.; Kuida, K.; Sakamaki, K.; Yonehara, 
S.;  Momoi, T. ER  stress  induces caspase-8 activation,  stimulating cytochrome  c  release  and 
caspase-9 activation. Exp. Cell Res. 2003, 283, 156–166. 
98.  Gething, M.J.; Sambrook, J. Protein folding in the cell. Nature 1992, 355, 33–45. 
99.  Stirling, P.C.; Lundin, V.F.; Leroux, M.R. Getting a grip on non-native proteins. EMBO Rep. 
2003, 4, 565–570. 
100.  Feldman, D.E.; Frydman, J. Protein folding in vivo: The importance of molecular chaperones. 
Curr. Opin. Struct. Biol. 2000, 10, 26–33. 
101.  Hatahet, F.; Ruddock, L.W.; Ahn, K.; Benham, A.; Craik, D.; Ellgaard, L.; Ferrari, D.; Ventura, 
S. Protein disulfide isomerase: A critical evaluation of its function in disulfide bond formation. 
Antioxid. Redox Signal. 2009, 11, 2807–2850. 
102.  Ellgaard, L.; Helenius, A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 
2003, 4, 181–191. 
103.  Ron, D.; Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. 
Nat. Rev. Mol. Cell Biol. 2007, 8, 519–529. 
104.  Hendershot, L.M. The ER chaperone BiP is a master regulator of ER function. Mt. Sinai J. Med. 
2004, 71, 289–297. 
105.  Boyce, M.; Yuan, J. Cellular response to endoplasmic reticulum stress: A matter of life or death. 
Cell Death Differ. 2006, 13, 363–373. 
106.  Schroder, M.; Kaufman, R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 
2005, 74, 739–789. 
107.  Szegezdi,  E.;  Logue,  S.E.;  Gorman,  A.M.;  Samali,  A.  Mediators  of  endoplasmic  reticulum  
stress-induced apoptosis. EMBO Rep. 2006, 7, 880–885. 
108.  Yoshida, H.; Matsui, T.; Yamamoto, A.; Okada, T.; Mori, K. XBP1 mRNA is induced by ATF6 
and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 
2001, 107, 881–891. 
109.  Calfon, M.; Zeng, H.; Urano, F.; Till, J. H.; Hubbard, S.R.; Harding, H.P.; Clark, S.G.; Ron, D. 
IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. 
Nature 2002, 415, 92–96. 
110.  Ye, J.; Rawson, R.B.; Komuro, R.; Chen, X.; Dave, U.P.; Prywes, R.; Brown, M.S.; Goldstein, 
J.L. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process 
SREBPs. Mol. Cell 2000, 6, 1355–1364. 
111.  Kadowaki, H.; Nishitoh, H.; Ichijo, H. Survival and apoptosis signals in ER stress: The role of 
protein kinases. J. Chem. Neuroanat. 2004, 28, 93–100. 
112.  Joyce, M.A.; Walters, K.A.; Lamb, S.E.; Yeh, M.M.; Zhu, L.F.; Kneteman, N.; Doyle, J.S.; 
Katze, M.G.; Tyrrell, D.L. HCV induces oxidative and ER stress, and sensitizes infected cells to 
apoptosis in SCID/Alb-uPA mice. PLoS Pathog. 2009, 5, e1000291. Toxins 2010, 2                         
 
 
1534 
113.  Lee, S.-Y.; Lee, M.-S.; Cherla, R.P.; Tesh, V.L. Shiga toxin 1 induces apoptosis through the 
endoplasmic  reticulum  stress  response  in  human  monocytic  cells.  Cell.  Microbiol.  2008,  10, 
770–780. 
114.  Marciniak,  S.J.;  Yun,  C.Y.;  Oyadomari,  S.;  Novoa,  I.;  Zhang,  Y.;  Jungreis,  R.;  Nagata,  K.; 
Harding, H.P.; Ron, D. CHOP induces death by promoting protein synthesis and oxidation in the 
stressed endoplasmic reticulum. Genes Dev. 2004, 18, 3066–3077. 
115.  Yamaguchi,  H.;  Wang,  H.G.  CHOP  is  involved  in  endoplasmic  reticulum  stress-induced 
apoptosis by enhancing DR5 expression in human carcinoma cells. J. Biol. Chem. 2004, 279, 
45495–45502. 
116.  McCullough, K.D.; Martindale, J.L.; Klotz, L.O.; Aw, T.Y.; Holbrook, N.J. Gadd153 sensitizes 
cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox 
state. Mol. Cell. Biol. 2001, 21, 1249–1259. 
117.  Paton, A.W.; Beddoe, T.; Thorpe, C.M.; Whisstock, J.C.; Wilce, M.C.; Rossjohn, J.; Talbot, 
U.M.; Paton, J.C. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. 
Nature 2006, 443, 548–552. 
118.  Wolfson, J.J.; May, K.L.; Thorpe, C.M.; Jandhyala, D.M.; Paton, J.C.; Paton, A.W. Subtilase 
cytotoxin activates PERK, IRE1 and ATF6 endoplasmic reticulum stress-signalling pathways. 
Cell. Microbiol. 2008, 10, 1775–1786. 
119.  Shi, Y.; Porter, K.; Parameswaran, N.; Bae, H.K.; Pestka, J.J. Role of GRP78/BiP degradation 
and ER stress in deoxynivalenol–induced interleukin-6 upregulation in the macrophage. Toxicol. 
Sci. 2009, 109, 247–255. 
120.  McConkey,  D.J.;  Orrenius,  S.  The  role  of  calcium  in  the  regulation  of  apoptosis.  Biochem. 
Biophys. Res. Commun. 1997, 239, 357–366. 
121.  Pinton,  P.;  Giorgi,  C.;  Siviero,  R.;  Zecchini,  E.;  Rizzuto,  R.  Calcium  and  apoptosis:  
ER-mitochondria Ca
2+ transfer in the control of apoptosis. Oncogene 2008, 27, 6407–6418. 
122.  Filippin,  L.;  Magalhaes,  P.J.;  Di  Benedetto,  G.;  Colella,  M.;  Pozzan,  T.  Stable  interactions 
between  mitochondria  and  endoplasmic  reticulum  allow  rapid  accumulation  of  calcium  in  a 
subpopulation of mitochondria. J. Biol. Chem. 2003, 278, 39224–39234. 
123.  Boya,  P.;  Cohen,  I.;  Zamzami,  N.;  Vieira,  H.L.;  Kroemer,  G.  Endoplasmic  reticulum  
stress-induced cell death requires mitochondrial membrane permeabilization. Cell Death Differ. 
2002, 9, 465–467. 
124.  Gil-Parrado,  S.;  Fernandez-Montalvan,  A.;  Assfalg-Machleidt,  I.;  Popp,  O.;  Bestvater,  F.; 
Holloschi, A.; Knoch, T.A.; Auerswald, E.A.; Welsh, K.; Reed, J.C.; Fritz, H.; Fuentes-Prior, P.; 
Spiess,  E.;  Salvesen,  G.S.;  Machleidt,  W.  Ionomycin-activated  calpain  triggers  apoptosis.  A 
probable role for Bcl-2 family members. J. Biol. Chem. 2002, 277, 27217–27226. 
125.  Cherla,  R.P.;  Lee,  S.-Y.;  Mulder,  R.A.;  Lee,  M.-S.;  Tesh,  V.L.  Shiga  toxin  1-induced 
proinflammatory  cytokine  production  is  regulated  by  the  phosphatidylinositol  
3-kinase/Akt/mammalian  target  of  rapamycin  signaling  pathway.  Infect.  Immun.  2009,  77,  
3919–3931. 
126.  Lee, S.-Y.; Cherla, R.P.; Tesh, V.L. Simultaneous induction of apoptotic and survival signaling 
pathways in macrophage-like THP-1 cells by Shiga toxin 1. Infect. Immun. 2007, 75, 1291–1302. Toxins 2010, 2                         
 
 
1535 
127.  Lee, M.-S.; Cherla, R.P.; Leyva-Illades, D.; Tesh, V.L. Bcl-2 regulates the onset of Shiga toxin 
1-induced apoptosis in THP-1 cells. Infect. Immun. 2009, 77, 5233–5344. 
128.  Youle, R.J.; Strasser, A. The BCL-2 protein family: Opposing activities that mediate cell death. 
Nat. Rev. Mol. Cell Biol .2008, 9, 47–59. 
129.  Giam, M.; Huang, D.C.; Bouillet, P. BH3-only proteins and their roles in programmed cell death. 
Oncogene 2008, 27 (Suppl. 1), S128–S136. 
130.  Lee, M.-S.; Cherla, R.P.; Lentz, E.K.; Leyva-Illades, D.; Tesh V.L. Signaling through C/EBP 
homology protein and death receptor 5, and calpain activation differentially regulates THP-1 cell 
maturation-dependent  apoptosis  induced  by  Shiga  toxin  type  1.  Infect.  Immun.  2010, 
doi:10.1128/IAI.00342-10. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 